Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBITDA: 2012-2025

Historic EBITDA for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$18.4 million.

  • Enanta Pharmaceuticals' EBITDA rose 38.41% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.3 million, marking a year-over-year increase of 29.86%. This contributed to the annual value of -$85.3 million for FY2025, which is 29.86% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its EBITDA stood at -$18.4 million for Q3 2025, which was up 2.68% from -$18.9 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year EBITDA high stood at -$18.4 million for Q3 2025, and its period low was -$39.5 million during Q1 2023.
  • Moreover, its 3-year median value for EBITDA was -$29.9 million (2024), whereas its average is -$28.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first slumped by 150.11% in 2021, then surged by 38.41% in 2025.
  • Enanta Pharmaceuticals' EBITDA (Quarterly) stood at -$30.4 million in 2021, then climbed by 1.30% to -$30.0 million in 2022, then declined by 16.24% to -$34.9 million in 2023, then soared by 32.51% to -$23.5 million in 2024, then soared by 38.41% to -$18.4 million in 2025.
  • Its EBITDA stands at -$18.4 million for Q3 2025, versus -$18.9 million for Q2 2025 and -$24.5 million for Q1 2025.